Skip to content
Gud Knight
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Community
  • Products
  • Partnering
  • Investors
    • Overview
    • Press Releases
    • Events & Webcasts
    • Financial Reports
    • Presentations & Fact Sheets
    • Product Pipeline
    • Shareholder Information
    • Governance
    • In the News
    • E-mail Alerts
  • Careers
  • Contact Us
  • Français
Site Search

In the News

Date

Title

31/07/2017
‘If Canada was efficient, I wouldn't exist:’ The miraculous success of Jonathan Ross Goodman
21/10/2016
EY Entrepreneur Of The Year Awards Québec 2016
20/09/2016
Knight Therapeutics "to get real" as it builds its commercial operations
12/04/2016
Forbion Capital Fund closes at $208 mln
15/03/2016
Knight Therapeutics reacquires leishmaniasis drug Impavido
23/02/2016
Knight CFO named finalist in the 2016 Aces of Finance Competition
08/10/2015
The lights are dimming for specialty pharma
05/05/2015
Knight Therapeutics: A solid long-term bet in the health care space
18/12/2014
U.S. program may alter the economics of Ebola vaccines
19/11/2014
Knight Therapeutics sells fast-track drug certificate
19/11/2014
Gilead Buys Shortcut For FDA Drug Review For $125 Million
19/11/2014
How Much? Gilead Pays $125M For an FDA Priority Review Voucher
19/11/2014
Gilead Buys Shortcut For FDA Drug Review For $125 Million
23/10/2014
Looking to repeat the feat
23/10/2014
Looking to repeat the feat

Investors

  • Overview
  • Press Releases
  • Events & Webcasts
  • Financial Reports
  • Presentations & Fact Sheets
  • Product Pipeline
  • Shareholder Information
  • Governance
  • In the News
  • E-Mail Alerts

© 2019 All rights reserved | Knight Therapeutics Inc.

  • Legal Notices
  • Privacy